Noom vs WePeptideRx

Neither Noom nor WePeptideRx has an FDA warning letter on record. On brand-name tirzepatide pen, Noom costs $4,200 less a year at standing rates: $349 a month against $699 a month at WePeptideRx. It is one of two products the two sell at comparable terms.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Noom / WePeptideRx

Noom logo

Noom

7.0/10

WePeptideRx logo

WePeptideRx

7.6/10

FDA warning letters
None on record
None on record
Pharmacy
None named in our record
None named in our record
Lowest standing price
$179/moCompounded semaglutide injection
$189/moCompounded semaglutide injection
States
No state list published
48 states
Checked
Prices captured Record checked September 2026
Prices captured Record checked October 2026

Neither Noom nor WePeptideRx pays us. Links to them earn nothing. Scores: Noom 7.0, WePeptideRx 7.6. How we are paid

What the record shows

  1. 01

    Neither Noom nor WePeptideRx has an FDA warning letter on record.

  2. 02

    Neither names the pharmacy that compounds its medication.

  3. 03

    On brand-name tirzepatide pen, Noom costs $4,200 less a year at standing rates: $349 a month against $699 a month at WePeptideRx. It is one of two products the two sell at comparable terms.

  4. 04

    Only WePeptideRx lists a price for compounded tirzepatide injection and brand-name semaglutide pen.

  5. 05

    WePeptideRx lists 48 states. Noom publishes no state list.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Noom

WePeptideRx

Compounded semaglutide injection

$179/moLower

$2,148 a year

$189/mo

$2,268 a year

Brand-name tirzepatide pen

$349/moLower

$4,188 a year

$699/mo

$8,388 a year

Compounded tirzepatide injection
Not sold or not priced

$199/mo

$2,388 a year

Brand-name semaglutide pen
Not sold or not priced

$399/mo

$4,788 a year

Price includes
Clinician visits, coaching
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
Not stated
None on monthly supplies; 90-day programs are paid up front
Refunds
Refunds only before a prescription is written; renewal charges are not refunded
Full refund if not approved; no refunds once medication is dispensed and shipped
Early-exit fee
Not stated
None stated

Read off each seller’s own pages. Noom: September 28, 2026. WePeptideRx: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Noom

7.0/10
  • $120 a year less on compounded semaglutide injection
  • $4,200 a year less on brand-name tirzepatide pen
  • Names no compounding pharmacy
  • Publishes no state list

The case for WePeptideRx

7.6/10
  • Sells compounded tirzepatide injection and brand-name semaglutide pen, which Noom does not price
  • Names no compounding pharmacy

Scores

Noom 7.0 · WePeptideRx 7.6 out of 10. Six weighted parts.

Value25%

5.8A
vs
B
5.6

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
7.5

Trust & Safety15%

6.5A
vs
B
7.5

Accessibility10%

5.0A
vs
B
9.7

Support10%

4.0A
vs
B
5.0

The score is the same formula for every seller. Payment does not enter it. Method

Noom vs WePeptideRx: questions

Neither Noom nor WePeptideRx has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Neither names the pharmacy that compounds its medication.
Noom, by $120 a year at standing rates. Noom: $179 a month, about $2,148 a year. WePeptideRx: $189 a month, about $2,268 a year.
Noom states you can cancel at any time; refunds: refunds only before a prescription is written; renewal charges are not refunded. WePeptideRx states you can cancel at any time; refunds: full refund if not approved; no refunds once medication is dispensed and shipped.
Neither Noom nor WePeptideRx pays us. Links to them earn nothing. Scores: Noom 7.0, WePeptideRx 7.6.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks